Credit: Adobe Stock
Wegovy and other GLP-1 agonist obesity-fighting drugs could eventually improve people's health so much that they will hurt the markets for other types of medical products and services.
But successful weight-loss drugs could increase the number of patients who get orthopedic surgery and some other procedures, according to analysts at Moody's Investors Service.
Recommended For You
Moody's rates companies' financial strength.
Analysts talked about the possible health care industry winners and losers in a thinner world in the firm's latest quarterly health care sector review.
The insurance analysts noted that U.S. insurers are unhappy with their Medicare Advantage plans but did not mention what they think about your employer clients' group health plans.
The medical devices and products team devoted a third of their update section to the possible impact of Wegovy, Saxenda and Zepbound.
The impact could start by hurting sales of the staplers, shears and other tools that surgeons use to help obese patients with bariatric surgery, the analysts predicted.
Effective weight-loss drugs could also reduce spending on devices used to support people with diabetes, heart disease, liver disease, kidney disease and sleep apnea, the analysts warned.
But the analysts suggested that device sellers could benefit when people with severe obesity lose enough weight to become eligible for orthopedic surgery.
Today, some physicians and health plans resist covering orthopedic surgery for people with a body mass index over 35.
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Allison Bell
Allison Bell, a senior reporter at ThinkAdvisor and BenefitsPRO, previously was an associate editor at National Underwriter Life & Health. She has a bachelor's degree in economics from Washington University in St. Louis and a master's degree in journalism from the Medill School of Journalism at Northwestern University. She can be reached through X at @Think_Allison.
